Andrew Hill Investment Advisors Inc. Grows Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

Andrew Hill Investment Advisors Inc. raised its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 79.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 13,634 shares of the biotechnology company's stock after buying an additional 6,044 shares during the period. United Therapeutics accounts for 3.6% of Andrew Hill Investment Advisors Inc.'s investment portfolio, making the stock its 13th biggest holding. Andrew Hill Investment Advisors Inc.'s holdings in United Therapeutics were worth $4,811,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Newbridge Financial Services Group Inc. bought a new stake in United Therapeutics during the fourth quarter valued at approximately $25,000. Millstone Evans Group LLC bought a new stake in United Therapeutics in the fourth quarter valued at $67,000. MassMutual Private Wealth & Trust FSB raised its stake in United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock worth $85,000 after buying an additional 58 shares in the last quarter. Jones Financial Companies Lllp lifted its position in United Therapeutics by 678.9% during the fourth quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company's stock valued at $104,000 after buying an additional 258 shares during the period. Finally, SBI Securities Co. Ltd. purchased a new position in shares of United Therapeutics during the fourth quarter valued at approximately $131,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. UBS Group upped their price target on United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a report on Wednesday, January 8th. HC Wainwright reaffirmed a "buy" rating and issued a $425.00 price objective on shares of United Therapeutics in a research note on Thursday, February 27th. Finally, StockNews.com downgraded shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Thursday, February 27th. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat.com, United Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $388.25.

United Therapeutics Trading Down 0.5 %

Shares of UTHR stock traded down $1.51 during trading hours on Tuesday, reaching $282.80. 274,562 shares of the company's stock were exchanged, compared to its average volume of 452,684. The company has a market cap of $12.70 billion, a price-to-earnings ratio of 12.42, a P/E/G ratio of 0.97 and a beta of 0.63. United Therapeutics Co. has a fifty-two week low of $230.39 and a fifty-two week high of $417.82. The stock's 50 day moving average is $321.83 and its 200-day moving average is $350.58.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million for the quarter, compared to the consensus estimate of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same quarter in the prior year, the company posted $4.36 earnings per share. Equities analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current year.

Insider Activity

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of the company's stock in a transaction that occurred on Thursday, April 3rd. The stock was sold at an average price of $306.18, for a total value of $3,367,980.00. Following the sale, the executive vice president now owns 36,781 shares in the company, valued at approximately $11,261,606.58. This represents a 23.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Tommy G. Thompson sold 2,500 shares of the firm's stock in a transaction on Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the sale, the director now owns 8,480 shares in the company, valued at approximately $2,703,424. This represents a 22.77 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 77,500 shares of company stock valued at $26,994,480 over the last ninety days. 11.90% of the stock is currently owned by insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.